January 5, 2018 / 7:40 AM / 9 months ago

BRIEF-Jiangsu Hengrui Medicine says license agreement on JAK1 inhibitor SHR0302 with U.S.-based firm Arcutis

Jan 5(Reuters) - Jiangsu Hengrui Medicine Co Ltd

* Says co signs license agreement with U.S.-based firm Arcutis regarding JAK1 inhibitor SHR0302

* Says co grants Arcutis an exclusive right to develop and sell JAK1 inhibitor SHR0302 in United States of America, European Union and Japan

* Says co will receive upfront and milestones payment of up to $223 million and sales commissions from Arcutis

Source text in Chinese: goo.gl/jvUdXK

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below